You are here

Novartis's US$475,000 cancer breakthrough heralds new era of cures


THE approval of Novartis's breakthrough therapy for a deadly form of leukaemia opened the door to a new class of treatments even as its US$475,000 price tag reignited the debate on how to value potentially life-saving drugs.

Demonstrating its willingness to clear...

Market voices on: